

September 23, 2014



# **Actinium Advisory Board Chairman to Participate in the Cancer Advance Boston: Focus on Innovation Conference at Harvard Medical School**

## **Dr. Joseph Jurcic's Panel Discussion to Focus on "Combination Therapy: Proposals for Success"**

NEW YORK, NY -- (Marketwired) -- 09/23/14 -- [Actinium Pharmaceuticals, Inc.](http://www.actiniumpharma.com) (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Joseph Jurcic, Chairman of Actinium's Clinical Advisory Board, will participate in the ["Combination Therapy: Proposals for Success"](#) panel discussion at the Cancer Advance Boston conference at Harvard Medical School. The panel is scheduled for Tuesday, September 30, 2014 from 1:50 to 2:30pm.

Dr. Jurcic will join some of the most distinguished cancer experts from academia and industry to discuss the increasing role of combination therapies in Oncology. The panel will explore topics such as effectively communicating the value of these treatments to patients and doctors alike, the collaborative process and rewards of successful partnerships, and the trends and sustainability of combination therapy pricing.

Joseph G. Jurcic, MD, Chairman of Actinium's Clinical Advisory Board, is also a Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. His main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. His research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease. He is the recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research. He is the author or coauthor of more than 80 articles and book chapters, has been the principal investigator on over 25 clinical trials, and regularly lectures at national and international meetings. He serves as a Leukemia Section Editor for The Oncologist.

### ***About Actinium Pharmaceuticals***

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and

bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical lomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of lomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

***Forward-Looking Statement for Actinium Pharmaceuticals, Inc.***

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.

Evan Smith, CFA

VP Investor Relations and Finance

+1 (646) 840-5442

Email: [esmith@actiniumpharma.com](mailto:esmith@actiniumpharma.com)

Source: Actinium Pharmaceuticals